The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

syndevrx.com

Executives

5

Board of Directors

1

SynDevRx Board of Director

1 Board of directors

SynDevRx has 1 board of directors, including Richard Love.

Name

Firm

Work History

Other Seats

Richard Love

Dr. Sawyers is Chairman of Memorial Sloan-Kettering Cancer Center's Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Jos&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;e and Henry R. Kravis Chair. HOPP capitalizes on recent advances in understanding cancer cell biology and the development of molecularly targeted drugs and other rationally based interventions. It brings together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer.</br> </br> Dr. Sawyerss work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. The promise of this approach is best exemplified by Dr. Sawyerss key role in the clinical development of imatinib (Gleevec&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;), which targets the molecular cause of chronic myeloid leukemia (CML) with minimal side effects. His group subsequently deciphered the molecular basis for resistance to imatinib. Based on this insight, he led the development of a second drug called dasatinib, which is effective in CML patients whose disease fails to respond to imatinib. He has extended this approach to other diseases, including prostate cancer and glioblastoma, through laboratory-based studies that suggest new treatment strategies now undergoing clinical testing.</br> </br> Dr. Sawyers came to Memorial Sloan-Kettering after nearly two decades at the University of California, Los Angeles (UCLA). He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He is also a Howard Hughes Medical Institute Investigator. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award.

SynDevRx

Name

Richard Love

Firm

Work History

Dr. Sawyers is Chairman of Memorial Sloan-Kettering Cancer Center's Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Jos&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;e and Henry R. Kravis Chair. HOPP capitalizes on recent advances in understanding cancer cell biology and the development of molecularly targeted drugs and other rationally based interventions. It brings together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer.</br> </br> Dr. Sawyerss work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. The promise of this approach is best exemplified by Dr. Sawyerss key role in the clinical development of imatinib (Gleevec&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;), which targets the molecular cause of chronic myeloid leukemia (CML) with minimal side effects. His group subsequently deciphered the molecular basis for resistance to imatinib. Based on this insight, he led the development of a second drug called dasatinib, which is effective in CML patients whose disease fails to respond to imatinib. He has extended this approach to other diseases, including prostate cancer and glioblastoma, through laboratory-based studies that suggest new treatment strategies now undergoing clinical testing.</br> </br> Dr. Sawyers came to Memorial Sloan-Kettering after nearly two decades at the University of California, Los Angeles (UCLA). He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He is also a Howard Hughes Medical Institute Investigator. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award.

Other Seats

SynDevRx

SynDevRx Management Team

5 Team Members

SynDevRx has 5 executives. SynDevRx's founder is James M. Shanahan. SynDevRx's current Founder, Chief Executive Officer, President is Bradley J. Carver.

Name

Work History

Title

Status

Bradley J. Carver

Founder, Chief Executive Officer, President

Current

James M. Shanahan

Founder

Current

David A Neafus

Chief Financial Officer

Current

Neal Salomon

Chief Medical Officer

Current

Peter Cornelius

Senior Director

Current

Name

Bradley J. Carver

James M. Shanahan

David A Neafus

Neal Salomon

Peter Cornelius

Work History

Title

Founder, Chief Executive Officer, President

Founder

Chief Financial Officer

Chief Medical Officer

Senior Director

Status

Current

Current

Current

Current

Current

You May Also Like

Konova Logo
Konova

Konova offers anti-obesity drug development

C
Cellogico

Cellogico Simulations Allow More Efficient Use Of Resources Through Highlighting Drug Targets With The Greatest Chance Of Success In The Early Stage Of Drug Development.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

A
Auxeris Therapeutics

Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development

R
Regene Med

RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.

P
Paloma Pharmaceuticals

Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.